Sugi Predict

Sugi Predict / Targets / CAMK4

CAMK4

Calcium/calmodulin-dependent protein kinase type IV · Q16566 · CAMK4 on Sugi Atlas →

5,708 patent compounds predicted against CAMK4, 4,587 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1249977 SCHEMBL1249977 0.57 2/20
SCHEMBL1249979 SCHEMBL1249979 0.57 2/20
Amg-900 Amg-900 (SCHEMBL503564) 1.00 1/20
Merestinib Merestinib (SCHEMBL679002) 1.00 1/20
Dabrafenib Dabrafenib (SCHEMBL806377) 1.00 1/20
Ceritinib Ceritinib (SCHEMBL1014329) 1.00 1/20
Merestinib Merestinib (SCHEMBL680728) 0.99 1/20
Dabrafenib Dabrafenib (SCHEMBL1127269) 0.95 1/20
SCHEMBL679128 SCHEMBL679128 0.91 1/20
SCHEMBL1014579 SCHEMBL1014579 0.89 1/20
SCHEMBL679216 SCHEMBL679216 0.86 1/20
SCHEMBL581178 SCHEMBL581178 0.84 1/20
SCHEMBL1545350 SCHEMBL1545350 0.84 1/20
SCHEMBL580354 SCHEMBL580354 0.84 1/20
SCHEMBL1127301 SCHEMBL1127301 0.83 1/20
SCHEMBL1127613 SCHEMBL1127613 0.83 1/20
SCHEMBL1127717 SCHEMBL1127717 0.83 1/20
SCHEMBL680715 SCHEMBL680715 0.82 1/20
SCHEMBL1545695 SCHEMBL1545695 0.82 1/20
SCHEMBL1545696 SCHEMBL1545696 0.82 1/20

Clinical trials — most relevant to CAMK4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
COMS for Chronic Ulcers Treatment PHASE4RECRUITING
Multimodal Versus Opioid aNalgesia in carDiAc Surgery PHASE4COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? PHASE2COMPLETED
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy PHASE2RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions PHASE2COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients PHASE1COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy EARLY_PHASE1RECRUITING
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study nanWITHDRAWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia nanRECRUITING
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury nanCOMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease nanUNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Pediatric Cardiomyopathy Mutation Analysis nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CAMK4 binder may also engage these)

ProteinNameSimilarity
P13234 — 1.000 P13234 →
P08414 — 0.998 P08414 →
Q7SY49 — 0.996 Q7SY49 →
O08605 — 0.994 O08605 →
O08875 — 0.993 O08875 →
Q66JF3 — 0.992 Q66JF3 →
Q66I46 — 0.992 Q66I46 →
P11730 — 0.992 P11730 →
MKNK1 MAP kinase-interacting serine/threonine-protein kinase 1 0.992 landscape →
Q852N6 — 0.992 Q852N6 →
Q8BRK8 — 0.992 Q8BRK8 →
CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 0.992 landscape →
Q9ZUZ2 — 0.991 Q9ZUZ2 →
CAMK2G Calcium/calmodulin-dependent protein kinase type II subunit gamma 0.991 landscape →
Q4G050 — 0.991 Q4G050 →
RPS6KB1 Ribosomal protein S6 kinase beta-1 0.991 landscape →
P08413 — 0.991 P08413 →
Q6TJY3 — 0.991 Q6TJY3 →
Q8BSK8 — 0.991 Q8BSK8 →
Q96QS6 — 0.990 Q96QS6 →
P51138 — 0.990 P51138 →
Q501V0 — 0.990 Q501V0 →
PSKH1 Serine/threonine-protein kinase H1 0.990 landscape →
O80673 — 0.990 O80673 →
Q8AXB4 — 0.990 Q8AXB4 →
DCLK1 Serine/threonine-protein kinase DCLK1 0.990 landscape →
Q91VB2 — 0.990 Q91VB2 →
Q38870 — 0.989 Q38870 →
Q8VZD5 — 0.989 Q8VZD5 →
Q6PFQ0 — 0.989 Q6PFQ0 →